Pictet Asset Management Holding SA Sells 148,194 Shares of Vaxcyte, Inc. $PCVX

Pictet Asset Management Holding SA lowered its position in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 14.4% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 881,435 shares of the company’s stock after selling 148,194 shares during the period. Pictet Asset Management Holding SA’s holdings in Vaxcyte were worth $40,669,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of PCVX. Royal Bank of Canada raised its stake in Vaxcyte by 115.2% during the first quarter. Royal Bank of Canada now owns 29,471 shares of the company’s stock worth $1,113,000 after buying an additional 15,774 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in Vaxcyte during the first quarter valued at $219,000. Caxton Associates LLP acquired a new stake in Vaxcyte during the 1st quarter worth about $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Vaxcyte by 8.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock worth $19,409,000 after acquiring an additional 41,034 shares in the last quarter. Finally, Cetera Investment Advisers raised its position in shares of Vaxcyte by 13.8% in the 2nd quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock worth $250,000 after acquiring an additional 932 shares in the last quarter. 96.78% of the stock is owned by institutional investors.

Vaxcyte Stock Down 2.4%

Shares of NASDAQ:PCVX opened at $57.32 on Thursday. Vaxcyte, Inc. has a twelve month low of $28.09 and a twelve month high of $65.00. The stock’s 50 day moving average is $58.73 and its 200-day moving average is $51.43. The firm has a market capitalization of $8.28 billion, a price-to-earnings ratio of -10.20 and a beta of 1.38.

Vaxcyte (NASDAQ:PCVX – Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($1.80) EPS for the quarter, missing analysts’ consensus estimates of ($1.46) by ($0.34). During the same quarter last year, the company posted ($1.12) EPS. Equities research analysts anticipate that Vaxcyte, Inc. will post -7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PCVX has been the topic of several research analyst reports. Needham & Company LLC upped their target price on Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Jefferies Financial Group restated a “buy” rating on shares of Vaxcyte in a report on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Wednesday, April 8th. Guggenheim reissued a “buy” rating and set a $116.00 target price on shares of Vaxcyte in a research note on Monday, February 2nd. Finally, BTIG Research upped their price objective on shares of Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $86.00.

Check Out Our Latest Stock Report on PCVX

Insider Transactions at Vaxcyte

In related news, COO Jim Wassil sold 7,395 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $58.88, for a total value of $435,417.60. Following the transaction, the chief operating officer owned 166,818 shares of the company’s stock, valued at approximately $9,822,243.84. This trade represents a 4.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Elvia Cowan sold 3,000 shares of Vaxcyte stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $60.00, for a total value of $180,000.00. Following the transaction, the chief accounting officer owned 28,975 shares of the company’s stock, valued at $1,738,500. This trade represents a 9.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 14,787 shares of company stock worth $867,031 in the last 90 days. 3.10% of the stock is currently owned by company insiders.

Vaxcyte Company Profile

(Free Report)

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.

Featured Stories

• Five stocks we like better than Vaxcyte

Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVX – Free Report).